Avenue Therapeutics, Inc. financial data

Symbol
ATXI on Nasdaq
Location
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 40.2 %
Return On Equity -285 %
Return On Assets -137 % +28.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.91M shares -85.6%
Common Stock, Shares, Outstanding 1.6M shares -82.1%
Entity Public Float 8.52M USD +189%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 1.6M shares +1379%
Weighted Average Number of Shares Outstanding, Diluted 8.2M shares +459%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.06M USD +26.4%
General and Administrative Expense 4.75M USD -26%
Operating Income (Loss) -11.8M USD +27.7%
Nonoperating Income (Expense) 69K USD -97.3%
Net Income (Loss) Attributable to Parent -3.08M USD -685%
Earnings Per Share, Basic 111 USD/shares -140%
Earnings Per Share, Diluted 0.06 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.6M USD +1513%
Assets 2.63M USD +423%
Accounts Payable, Current 78K USD -39.5%
Liabilities, Current 973K USD -80.6%
Liabilities 973K USD -80.6%
Retained Earnings (Accumulated Deficit) -101M USD -10.3%
Stockholders' Equity Attributable to Parent 2.61M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.65M USD
Liabilities and Equity 2.63M USD +423%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.12M USD -98.3%
Net Cash Provided by (Used in) Financing Activities 4.53M USD +46.1%
Common Stock, Shares Authorized 200M shares +167%
Common Stock, Shares, Issued 1.6M shares -82.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.71M USD +78.3%
Deferred Tax Assets, Valuation Allowance 35.7M USD +15.2%
Deferred Tax Assets, Gross 35.7M USD +15.2%
Deferred Tax Assets, Operating Loss Carryforwards 27.3M USD +6.46%
Preferred Stock, Shares Issued 250K shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 104M USD +17.9%
Preferred Stock, Shares Outstanding 250K shares
Share-based Payment Arrangement, Expense 1.02M USD -41%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%